PL1734992T3 - Ulepszone inaktywowane szczepionki fcv - Google Patents
Ulepszone inaktywowane szczepionki fcvInfo
- Publication number
- PL1734992T3 PL1734992T3 PL05705920T PL05705920T PL1734992T3 PL 1734992 T3 PL1734992 T3 PL 1734992T3 PL 05705920 T PL05705920 T PL 05705920T PL 05705920 T PL05705920 T PL 05705920T PL 1734992 T3 PL1734992 T3 PL 1734992T3
- Authority
- PL
- Poland
- Prior art keywords
- fcv
- improved
- vaccines
- inactivated
- inactivated fcv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000714201 Feline calicivirus Species 0.000 abstract 5
- 230000002163 immunogen Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000282323 Felidae Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16061—Methods of inactivation or attenuation
- C12N2770/16063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53784904P | 2004-01-21 | 2004-01-21 | |
| PCT/US2005/001721 WO2005072214A2 (en) | 2004-01-21 | 2005-01-19 | Improved inactivated fcv vaccines |
| EP05705920A EP1734992B1 (en) | 2004-01-21 | 2005-01-19 | Improved inactivated fcv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1734992T3 true PL1734992T3 (pl) | 2012-02-29 |
Family
ID=34825947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05705920T PL1734992T3 (pl) | 2004-01-21 | 2005-01-19 | Ulepszone inaktywowane szczepionki fcv |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1734992B1 (pl) |
| JP (1) | JP4873632B2 (pl) |
| CN (1) | CN1933852A (pl) |
| AT (1) | ATE526034T1 (pl) |
| CA (1) | CA2553805C (pl) |
| CY (1) | CY1112575T1 (pl) |
| DK (1) | DK1734992T3 (pl) |
| ES (1) | ES2374549T3 (pl) |
| PL (1) | PL1734992T3 (pl) |
| PT (1) | PT1734992E (pl) |
| SI (1) | SI1734992T1 (pl) |
| WO (1) | WO2005072214A2 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850978B2 (en) * | 1999-07-16 | 2010-12-14 | Merial Limited | Vaccine against feline calicivirus |
| CN101461941B (zh) * | 2007-12-20 | 2012-07-04 | 施怀哲维克有限公司 | 疫苗及其制备方法 |
| CN103773739B (zh) * | 2013-03-01 | 2016-06-15 | 上海启盛生物科技有限公司 | 一种猫泛白细胞减少症病毒减毒疫苗株及其应用 |
| CN112316129B (zh) | 2014-04-03 | 2025-01-28 | 勃林格殷格翰动物保健美国有限公司 | 猪流行性腹泻病毒疫苗 |
| ES2926813T3 (es) * | 2015-12-23 | 2022-10-28 | Intervet Int Bv | Vacuna contra el calicivirus felino |
| RO132299A3 (ro) * | 2017-06-06 | 2018-12-28 | Fântână Raul Sorin | Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active () |
| CN112877297A (zh) * | 2021-03-27 | 2021-06-01 | 哈尔滨元亨生物药业有限公司 | 一种利用生物反应器制备猫瘟热病毒单克隆抗体的方法 |
| CN114107170B (zh) * | 2021-11-12 | 2023-08-29 | 广东省华晟生物技术有限公司 | 猫肾悬浮细胞系及其构建方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド／免疫調節分子複合体 |
| AU5329300A (en) * | 1999-06-10 | 2001-01-02 | Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
| US6534066B1 (en) | 1999-07-16 | 2003-03-18 | Merial | Inactivated vaccine against feline calicivirosis |
| FR2796282B1 (fr) * | 1999-07-16 | 2001-10-26 | Merial Sas | Vaccin inactive contre la calicivirose feline |
| TR200202104T2 (tr) * | 1999-12-20 | 2002-12-23 | Agricultural Research Council | Mikroorganizmaların etkisiz hale getirilmesi yöntemi. |
-
2005
- 2005-01-19 DK DK05705920.6T patent/DK1734992T3/da active
- 2005-01-19 ES ES05705920T patent/ES2374549T3/es not_active Expired - Lifetime
- 2005-01-19 JP JP2006551242A patent/JP4873632B2/ja not_active Expired - Lifetime
- 2005-01-19 SI SI200531433T patent/SI1734992T1/sl unknown
- 2005-01-19 CA CA2553805A patent/CA2553805C/en not_active Expired - Lifetime
- 2005-01-19 PT PT05705920T patent/PT1734992E/pt unknown
- 2005-01-19 AT AT05705920T patent/ATE526034T1/de active
- 2005-01-19 EP EP05705920A patent/EP1734992B1/en not_active Expired - Lifetime
- 2005-01-19 WO PCT/US2005/001721 patent/WO2005072214A2/en not_active Ceased
- 2005-01-19 PL PL05705920T patent/PL1734992T3/pl unknown
- 2005-01-19 CN CNA2005800076279A patent/CN1933852A/zh active Pending
-
2011
- 2011-12-20 CY CY20111101260T patent/CY1112575T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005072214A2 (en) | 2005-08-11 |
| PT1734992E (pt) | 2011-12-21 |
| CN1933852A (zh) | 2007-03-21 |
| CA2553805C (en) | 2013-05-21 |
| CY1112575T1 (el) | 2016-02-10 |
| CA2553805A1 (en) | 2005-08-11 |
| HK1095035A1 (en) | 2007-04-20 |
| DK1734992T3 (da) | 2011-12-05 |
| WO2005072214A3 (en) | 2006-09-28 |
| EP1734992B1 (en) | 2011-09-28 |
| JP2007522127A (ja) | 2007-08-09 |
| ATE526034T1 (de) | 2011-10-15 |
| EP1734992A4 (en) | 2009-01-21 |
| ES2374549T3 (es) | 2012-02-17 |
| JP4873632B2 (ja) | 2012-02-08 |
| SI1734992T1 (sl) | 2012-01-31 |
| EP1734992A2 (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112575T1 (el) | Βελτιωμενα αδρανοποιημενα εμβολια fcv | |
| ZA202401922B (en) | Coronavirus vaccine formulations | |
| TW200806316A (en) | Yeast-based vaccine for inducing an immune response | |
| TNSN07387A1 (en) | C.perfringens alpha toxoid vaccine | |
| PL1635863T3 (pl) | Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| MY155236A (en) | Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant | |
| ZA200701176B (en) | Vaccines against aids comprising CMV/R-nucleic acid constructs | |
| GB2386072A (en) | Novel vaccine | |
| MY150706A (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
| MY161965A (en) | New influenza virus immunizing epitope | |
| WO2008127296A3 (en) | Methods and compositions for treating tularemia | |
| CA2763359C (en) | New human rotavirus strains and vaccines | |
| WO2008148057A3 (en) | Cationic lipids compositions and methods for enhancing immune responses to vaccines | |
| WO2023102448A3 (en) | Coronavirus vaccine formulations | |
| ZA200710011B (en) | A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein | |
| SG163598A1 (en) | Lawsonia vaccine and methods of use thereof | |
| WO2006063053A3 (en) | Methods of producing influenza vaccine compositions | |
| DE60336588D1 (de) | Verbesserte anthraximpfstoffe und abgabeverfahren | |
| WO2003060088A3 (en) | Viral vaccine production method | |
| AU2003278175A8 (en) | Vaccines of enhanced immunogenicity, and methods for preparing such vaccines | |
| WO2006078975A3 (en) | Improved vaccine against feline calicivirus | |
| WO2005123112A3 (en) | Method of enhancing the immune response to a vaccine | |
| ATE471155T1 (de) | Neues impfstoffadjuvans und dessen herstellung und verwendung | |
| GB0409559D0 (en) | Polypeptide |